Human Metabolome Technologies 6090.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 6090.T. It has been listed since 24 December 2013. In the fiscal year to 31 March 2026, it reported revenue of ¥1.42bn and net income of ¥200.4m. At that date it held total assets of ¥2.28bn and shareholders' equity of ¥1.83bn.

Human Metabolome Technologies, Inc. engages in the business of diagnostic technology and medical products. The company is headquartered in Tsuruoka-Shi, Yamagata-Ken. The company went IPO on 2013-12-24. The firm operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Yasuhiro OhataPresident, Chief Financial Officer, Representative Director, since 2020
• Mr. Atsushi NagashimaExecutive Officer, Director of Information System, since 2013
• Mr. Kenjiro KamiSenior Chief Director of Business, Director
• Mr. Hidehiro AndoIndependent Director
• Ms. Midori MizutaniIndependent Director
• Mr. Toshio NagaeIndependent Director
• Mr. Hajime NatsukariIndependent Director
• Ms. Michiyo UjiieIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.